New evidence added to the literature that paramagnetic rim lesions (PRLs) may be a biomarker of disability accumulation in ...

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis (MS) after a priority review by the US regulator.

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

Sanofi’s tolebrutinib, an investigational oral Bruton’s tyrosine kinase inhibitor, demonstrated a 31% delay in the onset of six-month confirmed disability progression in patients with non-active, ...

Data from an open-label trial showed that foralumab treatment eased fatigue and lessened disability for some people with ...

Vidofludimus calcium reduced the risk of 24-week confirmed disability worsening and slowed brain shrinkage in people with ...